A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find out if the study drug, ONTAK (denileukin
diftitox), can shrink or slow the growth of B-cell non-Hodgkin's lymphoma (NHL) in patients
whose disease has not responded to prior treatments, or has relapsed after an initial
response to prior treatments. The safety of treatment with ONTAK will also be studied. The
hypothesis is that patients with relapsed or refractory B-cell NHL and mild to moderate
myelosuppression treated with ONTAK at a new dosing regimen will respond sufficiently to
warrant further study.